Ritholtz Wealth Management Has $3 Million Stock Position in Pfizer Inc. $PFE

Ritholtz Wealth Management raised its holdings in shares of Pfizer Inc. (NYSE:PFE) by 32.4% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 117,836 shares of the biopharmaceutical company’s stock after purchasing an additional 28,828 shares during the period. Ritholtz Wealth Management’s holdings in Pfizer were worth $3,002,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also modified their holdings of PFE. Nwam LLC lifted its holdings in Pfizer by 7.5% in the third quarter. Nwam LLC now owns 43,630 shares of the biopharmaceutical company’s stock valued at $1,084,000 after buying an additional 3,044 shares during the period. Live Oak Investment Partners bought a new position in shares of Pfizer during the 3rd quarter valued at about $357,000. Country Trust Bank grew its position in shares of Pfizer by 10.3% in the 3rd quarter. Country Trust Bank now owns 4,923 shares of the biopharmaceutical company’s stock valued at $125,000 after purchasing an additional 460 shares during the period. Gilliland Jeter Wealth Management LLC raised its holdings in Pfizer by 17.9% during the 3rd quarter. Gilliland Jeter Wealth Management LLC now owns 22,597 shares of the biopharmaceutical company’s stock worth $576,000 after buying an additional 3,424 shares during the period. Finally, Deroy & Devereaux Private Investment Counsel Inc. lifted its stake in Pfizer by 15.5% in the third quarter. Deroy & Devereaux Private Investment Counsel Inc. now owns 9,675 shares of the biopharmaceutical company’s stock valued at $247,000 after buying an additional 1,300 shares in the last quarter. 68.36% of the stock is owned by institutional investors.

Pfizer Stock Performance

Shares of NYSE PFE opened at $25.68 on Friday. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.97 and a current ratio of 1.28. The stock has a 50 day moving average price of $25.35 and a 200 day moving average price of $24.99. The stock has a market capitalization of $146.01 billion, a PE ratio of 14.93 and a beta of 0.47. Pfizer Inc. has a 52 week low of $20.92 and a 52 week high of $27.69.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, November 4th. The biopharmaceutical company reported $0.87 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.79 by $0.08. The company had revenue of $16.65 billion for the quarter, compared to analysts’ expectations of $16.94 billion. Pfizer had a return on equity of 20.17% and a net margin of 15.65%.Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. Analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 6th. Stockholders of record on Friday, January 23rd will be paid a dividend of $0.43 per share. The ex-dividend date is Friday, January 23rd. This represents a $1.72 annualized dividend and a dividend yield of 6.7%. Pfizer’s payout ratio is currently 100.00%.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on PFE. UBS Group assumed coverage on shares of Pfizer in a research report on Tuesday, January 6th. They set a “neutral” rating and a $25.00 price objective for the company. The Goldman Sachs Group reissued a “neutral” rating and issued a $26.00 price target on shares of Pfizer in a research note on Wednesday, November 5th. Morgan Stanley decreased their price objective on Pfizer from $32.00 to $28.00 and set an “equal weight” rating for the company in a report on Friday, December 12th. Scotiabank assumed coverage on Pfizer in a research report on Thursday, November 13th. They issued a “sector outperform” rating and a $30.00 target price on the stock. Finally, Sanford C. Bernstein reaffirmed a “market perform” rating and set a $30.00 price target on shares of Pfizer in a research report on Friday, October 31st. Two research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, thirteen have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $27.88.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.